Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis.

Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis.

Item
http://www.wikidata.org/entity/Q34805412
Oclacitinib (APOQUEL(®)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy.Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia.A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis.Clinical efficacy of low-level laser therapy on localized canine atopic dermatitis severity score and localized pruritic visual analog score in pedal pruritus due to canine atopic dermatitis.A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs.Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA).Repeated oral dose tolerance in dogs treated concomitantly with ciclosporin and oclacitinib for three weeksTargeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.Cytokine Concentrations Measured by Multiplex Assays in Canine Peripheral Blood Samples.Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study.Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life.Oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis: results of a small prospective pilot study of client-owned cats.The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog.Development of a core outcome set for therapeutic clinical trials enrolling dogs with atopic dermatitis (COSCAD'18)
P2860

Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis.

Item
http://www.wikidata.org/entity/Q34805412
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Efficacy and safety of oclacit ...... th canine allergic dermatitis.
@ast
Efficacy and safety of oclacit ...... th canine allergic dermatitis.
@en
Efficacy and safety of oclacit ...... th canine allergic dermatitis.
@nl
type
label
Efficacy and safety of oclacit ...... th canine allergic dermatitis.
@ast
Efficacy and safety of oclacit ...... th canine allergic dermatitis.
@en
Efficacy and safety of oclacit ...... th canine allergic dermatitis.
@nl
prefLabel
Efficacy and safety of oclacit ...... th canine allergic dermatitis.
@ast
Efficacy and safety of oclacit ...... th canine allergic dermatitis.
@en
Efficacy and safety of oclacit ...... th canine allergic dermatitis.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P932
P356
P1433
P1476
Efficacy and safety of oclacit ...... th canine allergic dermatitis.
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P932